Clinical Trial Update: Infigratinib in Recurrent High-Grade Glioma Patients [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial of infigratinib in patients with recurrent high-grade glioma, including glioblastoma, was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma

Drugs mentioned

• Infigratinib (infigratinib)

Snippet

Sponsor: Nader Sanai | Conditions: Glioma, Glioblastoma | EARLY_Phase 1 | Status: TERMINATED | Results posted: 2025-10-24